New Data On Lucentis (ranibizumab) - Continued Treatment Achieves Sustained Benefits In Visual Acuity And Quality Of Life In Patients With AMD
The ANCHOR (Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration) study randomised patients with predominantly classic neovascular age-related macular degeneration in a 1:1:1 ratio to monthly intravitreal injections of ranibizumab (0.3 mg or 0.5 mg) plus sham verteporfin therapy or monthly sham injections plus active verteporfin therapy (photodynamic therapy, PDT; the current standard of care).
Results showed that 89.9% of patient randomised to Lucentis lost fewer than 15 letters on a visual acuity chart at 24 months compared to 65.7% of those treated with PDT (p
Noile date de pe Lucentis (ranibizumab) - a continuat tratamentul susþinut realizeazã beneficii în acuitãþii vizuale ºi a calitãþii vieþii la pacienþii cu DMLV - New Data On Lucentis (ranibizumab) - Continued Treatment Achieves Sustained Benefits In Visual Acuity And Quality Of Life In Patients With AMD - articole medicale engleza - startsanatate